The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5454
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice ; volume:36 ; number:9 ; day:21 ; month:3 ; year:2022 ; pages:1725-1734 ; date:9.2022
Eye ; 36, Heft 9 (21.3.2022), 1725-1734, 9.2022
- Urheber
-
Pearce, Ian
Amoaku, Winfried
Bailey, Clare
Downey, Louise
Gale, Richard
Ghanchi, Faruque
Hamilton, Robin
Mahmood, Sajjad
Menon, Geeta
Nosek, Jenny
Talks, James
Yang, Yit
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-022-02008-3
- URN
-
urn:nbn:de:101:1-2022110718310658263475
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pearce, Ian
- Amoaku, Winfried
- Bailey, Clare
- Downey, Louise
- Gale, Richard
- Ghanchi, Faruque
- Hamilton, Robin
- Mahmood, Sajjad
- Menon, Geeta
- Nosek, Jenny
- Talks, James
- Yang, Yit
- SpringerLink (Online service)
Ähnliche Objekte (12)
Gains in the current understanding of managing neovascular AMD with brolucizumab
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in non-neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
The Changing Landscape of Alopecia Areata: The Translational Landscape
Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
The Changing Business Landscape of Romania
The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden – data from the Swedish Macula Register
Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD
Gains in the current understanding of managing neovascular AMD with brolucizumab
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in non-neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
The Changing Landscape of Alopecia Areata: The Translational Landscape
Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
The Changing Business Landscape of Romania
The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden – data from the Swedish Macula Register
Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD
Gains in the current understanding of managing neovascular AMD with brolucizumab
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in non-neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
The Changing Landscape of Alopecia Areata: The Translational Landscape
Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
The Changing Business Landscape of Romania
The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden – data from the Swedish Macula Register